Presseaussendungen zu "Novo Nordisk"

194 Aussendungen
vorige Seite Seite 1 von 13 nächste Seite

Das Shared Services and Outsourcing Network präsentiert die Nordic Business Transformation: Nordic BT 2018 transformiert die Backoffices der Zukunft

Wandel oder Untergang ist die Botschaft des Tages - Wandel wird der bestimmende Faktor für den Erfolg zukünftiger Unternehmen sein.

OTS0005
12.07.2018 05:41

Tresiba® Demonstrated Significantly Improved Blood Sugar Control and Lower Rates of Hypoglycaemia Versus Insulin Glargine U300 in Real-World Evidence Study

Adults with type 2 diabetes treated with Tresiba® (insulin degludec injection) had a significant reduction in HbA1c and a 30% lower rate of hypoglycaemic episodes after starting basal insulin

OTE0004
23.06.2018 16:13

Ozempic® Provided Greater Weight Reductions for Adults With a Baseline BMI >=25kg

m2 Than Those With Lower Baseline BMI <25kg/m2, in a SUSTAIN 7 Post-hoc Analysis

OTE0003
23.06.2018 16:10

Oral Semaglutide Demonstrated Significant Reduction in Blood Sugar vs Placebo in PIONEER 1 Trial

Oral semaglutide, an investigational GLP-1 analogue taken as a once-daily tablet, achieved significant reductions in blood sugar versus placebo in adults with type 2 diabetes, according to findings from the …

OTE0002
23.06.2018 16:07

Real-World Evidence Shows Clinically Meaningful Weight Loss in People Receiving Saxenda®

People treated with Saxenda® (liraglutide 3 mg) for weight management lost an average of 8.1 kg after six months in a real-world clinical setting, in combination with diet and exercise.

OTE0004
24.05.2018 08:03

Head-to-Head Trial Shows Refixia® Achieves Greater Total Factor IX Exposure in People With Haemophilia B Than Recombinant Factor IX-Fc Fusion Protein

Adults with haemophilia B who received a single dose Refixia® (nonacog beta pegol; N9-GP) achieved greater total factor IX exposure than those treated with rFIXFc (recombinant factor IX-Fc fusion protein).

OTE0002
21.05.2018 11:47

NovoEight® Maintains Potency When Stored at 40ºC Offering People With Haemophilia A Increased Flexibility in Their Daily Lives

A new long term stability study has shown that haemophilia A treatment NovoEight® (turoctocog alfa) remains potent after three months exposure to temperatures of 40ºC.[1] The results were presented today …

OTE0001
21.05.2018 11:21

BioLamina and Novo Nordisk Partner to Advance Stem Cell Based Therapies for Three Common Medical Conditions

BioLamina and collaborators have partnered with Novo Nordisk A/S (Novo Nordisk), a Danish multinational pharmaceutical company, allowing Novo Nordisk to develop novel stem cell based therapies based on …

OTE0002
16.05.2018 08:02

Dr. Philip Just Larsen zum Chief Scientific Officer (CSO) ernannt

Grünenthal hat heute bekannt gegeben, dass Philip Just Larsen zum Chief Scientific Officer (CSO) und Mitglied der Konzerngeschäftsführung ernannt worden ist.

OTS0092
23.04.2018 12:01

Indegene entwirft in seiner "Digital Maturity Study" das am weitesten längsausgerichtete Modell für biowissenschaftliche Firmen

Cross-Integration der digitalen Infrastruktur durch hypersegmentierte Channel- und Content-Mischung für verbesserte Kundenzentrierung

OTS0002
23.02.2018 04:25

Semaglutide Demonstrated Significant Reductions in Blood Sugar and Weight Compared with Dulaglutide; Results Published in The Lancet Diabetes & Endocrinology

Results from the SUSTAIN 7 trial, which investigated the efficacy and safety of 0.5 mg semaglutide compared with 0.75 mg dulaglutide and 1.0 mg semaglutide compared with 1.5 mg dulaglutide, when added to …

OTE0001
01.02.2018 09:32

Xultophy® Significantly Reduces Blood Sugar Levels, Body Weight and Risk of Hypoglycaemia for People With Type 2 Diabetes in Real-World Setting

Newly published data from real-world European clinical practice has shown that Xultophy® (insulin degludec/liraglutide) significantly reduced blood sugar levels in people with type 2 diabetes after six …

OTE0001
11.12.2017 09:03

Ryzodeg® Significantly Reduces the Risk of Low Blood Sugar in People With Type 2 Diabetes who Fast During Ramadan

In people with type 2 diabetes who fast during Ramadan, Ryzodeg® (insulin degludec/insulin aspart) reduced the overall rate of low blood sugar (hypoglycaemia) including severe episodes by 62% and the rate …

OTE0003
07.12.2017 09:48
in Chronik
vorige Seite nächste Seite